Alnylam Pharmaceuticals | ALNY - Assets


Alnylam Pharmaceuticals reported $5.13B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Moderna USD 11.49B 850M Mar/2026
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novartis USD 110.95B 3.66B Dec/2025
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Takeda JPY 15.45T 44.34B Mar/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026